Advancements in Synthetic Small Molecules as Anti-cancer Therapeutics
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 374
Special Issue Editors
Interests: medicinal chemistry; organic synthesis; pharmacology; drug discovery; molecular docking; anti-cancer activities
Special Issues, Collections and Topics in MDPI journals
Interests: design, synthesis, and biological evaluation of small molecule inhibitors targeting various enzymes and proteins
Special Issue Information
Dear Colleagues,
Cancer is the uncontrolled, rapid, and pathological proliferation of abnormal cells, which is a tremendous problem worldwide today. According to the World Health Organization (WHO), cancer is the second leading cause of death globally. Its treatment remains challenging for the scientific community. One major problem with its treatment is that most of the currently available drugs are unable to differentiate between normal and abnormal cells, which is the reason behind their side effects such as thrombocytopenia, anemia, delirium, edema, etc. Drug resistance is also an issue with the current treatment of cancer. Anticancer therapeutics refer to treatments or drugs that are used to combat cancer. Anticancer small molecules, also known as small molecule inhibitors, are a type of therapeutic agent used in cancer treatment. These molecules are small organic compounds that can penetrate cells and interact with specific targets involved in cancer cell growth and survival. They work by inhibiting or interfering with the activity of proteins or pathways that are essential for cancer cell proliferation. These molecules have advantages in some aspects, such as pharmacokinetic (PK) properties, costs, patient compliance, and drug storage and transportation. This Special Issue welcomes research and up-to-date review articles addressing current research on anticancer therapeutics, with a particular focus on discovering novel anti-cancer small molecules.
Dr. Amandeep Singh
Guest Editor
Dr. Harbinder Singh
Dr. Anu Rani
Co-Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- anticancer therapeutics
- cancer targeting
- small molecules
- drug resistance
